Jang HY - Search Results

1

Risk factors of Hypersensitivity Reactions to Carboplatin: A Systematic Review and Meta-analysis.

Jang HY, Choi B, Kim IW, Kang HR, Oh JM. Jang HY, et al. J Allergy Clin Immunol Pract. 2024 Dec 24:S2213-2198(24)01264-9. doi: 10.1016/j.jaip.2024.12.021. Online ahead of print. J Allergy Clin Immunol Pract. 2024. PMID: 39725314

2

Impact of depression on change in coronary heart disease risk status: the Korean Genome and Epidemiology Study (KoGES).

Jang HY, Song YK, Kim JH, Kim MG, Han N, Lee HY, Kim IW, Oh JM. Jang HY, et al. Ther Clin Risk Manag. 2018 Jan 10;14:121-128. doi: 10.2147/TCRM.S149501. eCollection 2018. Ther Clin Risk Manag. 2018. PMID: 29391804 Free PMC article.

3

The effect of selective serotonin reuptake inhibitors on major adverse cardiovascular events: a meta-analysis of randomized-controlled studies in depression.

Kim Y, Lee YS, Kim MG, Song YK, Kim Y, Jang H, Kim JH, Han N, Ji E, Kim IW, Oh JM. Kim Y, et al. Int Clin Psychopharmacol. 2019 Jan;34(1):9-17. doi: 10.1097/YIC.0000000000000238. Int Clin Psychopharmacol. 2019. PMID: 30096056

4

Major Adverse Cardiovascular Events in Antidepressant Users Within Patients With Ischemic Heart Diseases: A Nationwide Cohort Study.

Kim JH, Song YK, Jang HY, Shin JY, Lee HY, Ahn YM, Oh JM, Kim IW. Kim JH, et al. Among authors: jang hy. J Clin Psychopharmacol. 2020 Sep/Oct;40(5):475-481. doi: 10.1097/JCP.0000000000001252. J Clin Psychopharmacol. 2020. PMID: 32796394

5

Cysteinyl Leukotriene Receptor Antagonists Associated With a Decreased Incidence of Cancer: A Retrospective Cohort Study.

Jang HY, Kim IW, Oh JM. Jang HY, et al. Front Oncol. 2022 Apr 7;12:858855. doi: 10.3389/fonc.2022.858855. eCollection 2022. Front Oncol. 2022. PMID: 35463337 Free PMC article.

6

Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data.

Jang HY, Kim IW, Oh JM. Jang HY, et al. Front Pharmacol. 2022 Aug 30;13:928121. doi: 10.3389/fphar.2022.928121. eCollection 2022. Front Pharmacol. 2022. PMID: 36110539 Free PMC article.

7

Carfilzomib's Real-World Safety Outcomes in Korea: Target Trial Emulation Study Using Electronic Health Records.

Jang HY, Lee HK, Kim CJ, Yoon SS, Kim IW, Oh JM. Jang HY, et al. Int J Environ Res Public Health. 2022 Oct 19;19(20):13560. doi: 10.3390/ijerph192013560. Int J Environ Res Public Health. 2022. PMID: 36294140 Free PMC article.

8

Drug repurposing using meta-analysis of gene expression in Alzheimer's disease.

Jang HY, Oh JM, Kim IW. Jang HY, et al. Front Neurosci. 2022 Nov 10;16:989174. doi: 10.3389/fnins.2022.989174. eCollection 2022. Front Neurosci. 2022. PMID: 36440278 Free PMC article.

9

Comparative Safety Analysis of Empagliflozin in Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease versus Normal Kidney Function: A Nationwide Cohort Study in Korea.

Jang HY, Kim IW, Oh JM. Jang HY, et al. Pharmaceutics. 2023 Sep 27;15(10):2394. doi: 10.3390/pharmaceutics15102394. Pharmaceutics. 2023. PMID: 37896154 Free PMC article.

10

Fibrates and risk of congenital malformations: a nationwide cohort study in South Korea.

Kay HY, Jang HY, Kim IW, Oh JM. Kay HY, et al. Among authors: jang hy. Arch Gynecol Obstet. 2024 Oct;310(4):1967-1973. doi: 10.1007/s00404-023-07357-2. Epub 2024 Mar 29. Arch Gynecol Obstet. 2024. PMID: 38553644 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

319 results

Search Page

Filters